Tacrolimus (all routes)


Study Exclusion reasons Rmk Reference
Hebral, 2014 EXCLUDED: One women was receiving mycophenolic acid at conception (unknown co-allocation). This co-exposure does not allow an assessment of tacrolimus.

Hebral Nephrol. Dial. Transplant. 2014; 29:1786-93 10.1093/ndt/gfu208
Kamarajah, 2019 EXCLUDED: Immunosuppresion with Tacrolimus was alone or in combination (3 co-exposures with mycophenolate mofetil). This co-exposure does not allow an assessment of tacrolimus.

Kamarajah Clin. Gastroenterol. Hepatol. 2019; 17:1398-1404.e1 10.1016/j.cgh.2018.11.055
You, 2014 EXCLUDED: Some exposure including mycophenolate mofetil (n=6 in unknown allocation). This co-exposure does not allow an assessment of tacrolimus.

You Clin Transplant 2014; 28:699-706 10.1111/ctr.12367
Coscia, 2014 EXCLUDED: Between 1-23% of mycophenolate exposure during pregnancy. This co-exposure does not allow an assessment of tacrolimus.

Armenti Nephrol News Issues 2000; 14:S11

Armenti Transplant Rev (Orlando) 2008; 22:223-40 10.1016/j.trre.2008.05.001

Armenti Liver Transpl 2000; 6:671-85 10.1053/jlts.2000.18703

Armenti, V.T. Drugs 2002; 62:2361-. 10.2165/00003495-200262160-00004

Coscia Best Pract Res Clin Obstet Gynaecol 2014; 28:1174-87 10.1016/j.bpobgyn.2014.07.020
Christopher, 2006 EXCLUDED: Mycophenolate mofetil was used in conjunction with tacrolimus in 2 cases. This co-exposure does not allow an assessment of tacrolimus.

Christopher Liver Transpl. 2006; 12:1138-43 10.1002/lt.20810
Nakagawa, 2015 inadequate or absent control group EXCLUDED: no pregnancy in the control group.=> No adequate control group.

Nakagawa Am. J. Reprod. Immunol. 2015; 73:353-61 10.1111/aji.12338
Armenti, 1998 inadequate or absent control group EXCLUDED: not a comparative study.

Armenti Drug Saf 1998; 19:219-32 10.2165/00002018-199819030-00005
Gorgulu, 2010 inadequate or absent control group

Gorgulu Clin. Exp. Nephrol. 2010; 14:244-7 10.1007/s10157-009-0263-6
Baskiran, 2017 inadequate or absent control group

Baskiran Transplant. Proc. 2017; 49:1875-1878 10.1016/j.transproceed.2017.04.023
Armenti, 2003 inadequate or absent control group EXCLUDED: not a comparative study.

Armenti, V.T. Pediatric Clinics of North America 2003; 50:1543-. 10.1016/S0031-3955(03)00130-5
Jabiry-Zieniewicz, 2005 case report or case series

Jabiry-Zieniewicz Transplant. Proc. 2005; 37:1197-200 10.1016/j.transproceed.2005.01.011
Jain, 1997 case report or case series

Jain Transplantation 1997 64:559–565

Jabiry-Zieniewicz, 2007 case report or case series

Jabiry-Zieniewicz Transplant. Proc. 2007; 39:2796-9 10.1016/j.transproceed.2007.09.011
Thakrar, 2014 case report or case series

Thakrar J. Heart Lung Transplant. 2014; 33:593-8 10.1016/j.healun.2014.02.008
Schramm, 2006 not relevant exposure

Schramm Am. J. Gastroenterol. 2006; 101:556-60 10.1111/j.1572-0241.2006.00479.x
Hoekstra, 2018 not relevant exposure

Hoekstra Eur J Gastroenterol Hepatol 2018; 30:704-708 10.1097/MEG.0000000000001117
Narayanan, 2019 not about fetal exposure EXCLUDED: Tacrolimus exposure not during pregnancy.

Narayanan, M. Br. J. Haematol. 2019; 185:72-. 10.1111/bjh.15854
Kociszewska-Najman, 2016 not relevant outcome

Kociszewska-Najman Transplant. Proc. 2016; 48:1556-60 10.1016/j.transproceed.2016.01.088
Sargin, 2019 not relevant outcome EXCLUDED: not relevant outcome.

Sargin Turk J Med Sci 2019; 49:1736-1741 10.3906/sag-1905-59
Stoumpos, 2016 not relevant outcome

Stoumpos Clin Transplant 2016; 30:673-81 10.1111/ctr.12732
Feyaerts, 2021 not relevant outcome EXCLUDED: They defined the effects of kidney transplantation on the immune cell composition during pregnancy. Not relevant outcomes

Feyaerts Front Immunol 2021; 12:735564 10.3389/fimmu.2021.735564
Jain, 2004 not relevant outcome

Jain Transplantation 2004; 77:897-902 10.1097/01.tp.0000117564.50117.fb
Sciarrone,, 2021 data not abstractable EXCLUDED: data not extractable 'Cyclosporine was used in 25 and Tacrolimus in 37 patients, with no different maternal and newborn outcomes between the two drugs.' (only an abstract).

Sciarrone, S.S. Dig. Liver Dis. 2021; 53:S12-. 10.1016/j.dld.2020.12.037
Armenti, 2008 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Completely overlapped with the publication of Coscia et al. 2014: same data source the National Transplantation Pregnancy Registry (NTPR) and longer study period 1991 - 2013.

Armenti Transplant Rev (Orlando) 2008; 22:223-40 10.1016/j.trre.2008.05.001
Armenti, 2000 book chapter (without original data)

Armenti Nephrol News Issues 2000; 14:S11

Bar, 2003 Studies without separate analysis of the considered drug/class from other drugs/class

Bar Am. J. Med. Genet. A 2003; 116A:31-6 10.1002/ajmg.a.10817
Bhagra, 2016 Studies without separate analysis of the considered drug/class from other drugs/class

Bhagra Clin Transplant 2016; 30:1059-65 10.1111/ctr.12788
Bramham, 2013 Studies without separate analysis of the considered drug/class from other drugs/class

Bramham Clin J Am Soc Nephrol 2013; 8:290-8 10.2215/CJN.06170612
Schreiber-Zamora, 2019 Studies without separate analysis of the considered drug/class from other drugs/class

Schreiber-Zamora J. Matern. Fetal. Neonatal. Med. 2019; 32:1523-1527 10.1080/14767058.2017.1407754
Stokkeland, 2016 Studies without separate analysis of the considered drug/class from other drugs/class

Stokkeland Liver Int. 2016; 36:76-83 10.1111/liv.12901
Westbrook, 2012 Studies without separate analysis of the considered drug/class from other drugs/class

Westbrook J. Autoimmun. 2012; 38:J239-44 10.1016/j.jaut.2011.12.002
Schreiber-Zamora, 2014 Studies without separate analysis of the considered drug/class from other drugs/class

Schreiber-Zamora Transplant. Proc. 2014; 46:2798-801 10.1016/j.transproceed.2014.09.061
Piccoli, 2016 Studies without separate analysis of the considered drug/class from other drugs/class

Piccoli Nephrol. Dial. Transplant. 2016; 31:1957-1965 10.1093/ndt/gfw232
Mohamed-Ahmed, 2014 Studies without separate analysis of the considered drug/class from other drugs/class

Mohamed-Ahmed PLoS ONE 2014; 9:e89151 10.1371/journal.pone.0089151
Lin, 2014 Studies without separate analysis of the considered drug/class from other drugs/class

Lin Lupus Sci Med 2014; 1:e000024 10.1136/lupus-2014-000024
Kwek, 2015 Studies without separate analysis of the considered drug/class from other drugs/class

Kwek J. Obstet. Gynaecol. Res. 2015; 41:1337-44 10.1111/jog.12736
Kociszewska-Najman,, 2017 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: not enough details on the tacrolimus-exposed group (abstract).

Kociszewska-Najman, B. Eur. J. Pediatr. 2017; 176:1515-. 10.1007/s00431-017-2979-8
Candido, 2016 Studies without separate analysis of the considered drug/class from other drugs/class

Candido J Bras Nefrol 2016; 38:421-426 10.5935/0101-2800.20160067
Kaoru, 2021 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: only an abstract, not enough information regarding the type of exposure.

Kaoru, N. J. Obstet. Gynaecol. Res. 2021; 47:2924-. 10.1111/jog.14876
Akarsu, 2016 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: analysis performed on illness status, without distinction between treatments.

Akarsu Transplant. Proc. 2016; 48:3373-3377 10.1016/j.transproceed.2016.09.033
Armenti, 2013 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: only an abstract, not enough information on the tacrolimus-exposed group.

Armenti, V.T. Birth Defects Res. Part A Clin. Mol. Teratol. 2013; 97:297-. 10.1002/bdra.23146
Gutiérrez, 2005 Studies without separate analysis of the considered drug/class from other drugs/class

Gutiérrez Transplant. Proc. 2005; 37:3721-2 10.1016/j.transproceed.2005.09.175
Cowan, 2012 Review articles, letter to editor, editorial, comments

Cowan Cardiol Clin 2012; 30:441-52 10.1016/j.ccl.2012.05.001
Díaz, 2008 Review articles, letter to editor, editorial, comments

Díaz Nefrologia 2008; 28:174-7

Psenak, 2012 Review articles, letter to editor, editorial, comments EXCLUDED: Only a litterature review.

Psenak Z Rheumatol 2012; 71:420-9 10.1007/s00393-012-0990-z
Petri, 2003 Review articles, letter to editor, editorial, comments

Petri 2003 Autoimmunity

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons